Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Medtronic
Mallinckrodt
McKesson
AstraZeneca

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR DEPACON


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Depacon

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000439 ↗ Drug Treatment for Alcoholics With Bipolar Disorder Completed University of Pittsburgh Phase 2 2000-10-01 The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in treating individuals with alcohol dependence and comorbid bipolar disorder.
NCT00000439 ↗ Drug Treatment for Alcoholics With Bipolar Disorder Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 2000-10-01 The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in treating individuals with alcohol dependence and comorbid bipolar disorder.
NCT00203242 ↗ An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches. Completed Abbott N/A 2003-07-01 The purpose of this study is to collect and evaluate information on the use of Depakote Extended Release (ER) and Depacon Intravenous (IV) in patients with cluster headaches. Patients who are currently in a cluster cycle will be treated with 2 consecutive days of IV Depacon followed by oral Depakote ER. Patients will receive a total of 1,000mg of Depacon and 1,000mg of Depakote ER each day. Patients may have a 3rd day of IV Depacon followed by oral Depakote ER if the primary investigator believes it to be beneficial. The patient is then sent home on oral Depakote ER. The dose of Depakote ER can range from 500mg to 2,000mg this dose is to be determined by the primary investigator. The patient will continue the oral Depakote ER until the end of their cluster cycle or for a maximum of 6 weeks, which ever comes first.
NCT00203242 ↗ An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches. Completed Thomas Jefferson University N/A 2003-07-01 The purpose of this study is to collect and evaluate information on the use of Depakote Extended Release (ER) and Depacon Intravenous (IV) in patients with cluster headaches. Patients who are currently in a cluster cycle will be treated with 2 consecutive days of IV Depacon followed by oral Depakote ER. Patients will receive a total of 1,000mg of Depacon and 1,000mg of Depakote ER each day. Patients may have a 3rd day of IV Depacon followed by oral Depakote ER if the primary investigator believes it to be beneficial. The patient is then sent home on oral Depakote ER. The dose of Depakote ER can range from 500mg to 2,000mg this dose is to be determined by the primary investigator. The patient will continue the oral Depakote ER until the end of their cluster cycle or for a maximum of 6 weeks, which ever comes first.
NCT00609245 ↗ Effect of Valproic Acid Concentration on Photic Response Completed Abbott Phase 4 2007-12-01 We are trying to learn if small changes in the amount of a valproate in the blood (given through an IV) will change the way the brain reacts to flashing lights.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Depacon

Condition Name

Condition Name for Depacon
Intervention Trials
Shock,Hemorrhagic 2
Photosensitive Epilepsy 1
Trauma 1
Alcoholism 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Depacon
Intervention Trials
Epilepsy 2
Shock, Hemorrhagic 2
Squamous Cell Carcinoma of Head and Neck 1
Headache 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Depacon

Trials by Country

Trials by Country for Depacon
Location Trials
United States 7
Australia 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Depacon
Location Trials
Michigan 2
Pennsylvania 2
Massachusetts 1
Tennessee 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Depacon

Clinical Trial Phase

Clinical Trial Phase for Depacon
Clinical Trial Phase Trials
Phase 4 1
Phase 2 1
Phase 1/Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Depacon
Clinical Trial Phase Trials
Completed 6
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Depacon

Sponsor Name

Sponsor Name for Depacon
Sponsor Trials
Dr. Hasan Alam 2
Abbott 2
Vanderbilt University Medical Center 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Depacon
Sponsor Trials
Other 7
Industry 3
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Colorcon
Mallinckrodt
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.